videotape of each trial participant giving informed consent -for a vaccine trial, that could mean video taping thousands of patients. Meanwhile, several other companies have closed their Indian branches. In October the clinical trials contractor Quintiles, based in Durham, North Carolina, closed its phase I unit in Hyderabad, and on 31 January AstraZeneca, headquartered in London, announced plans to shut its Bangalore centre, although both companies maintain other facilities in India and say that the closures are due to restructuring. "The whole thing has had a very chilling effect for clinical trials and foreign sponsors, " says Amita Gupta, a researcher on ACTG trials at Johns Hopkins University in Baltimore, Maryland. "The motivation is coming from the right place, but the government overstepped. "
The health ministry that oversees the DCGI recognized this overstep and asked for recommended changes from a six-member panel led by Ranjit Roy Chaudhury, a pharmacologist and a former board member of the Medical Council of India. The panel's July report gave various fixes, among which was a recommendation to scrap compensation for participants who received a placebo.
They also specified a new formula to calculate how much a participant who was harmed by a trial should be paid and suggested the formation of a national board to approve institutions' ethics committees, which are responsible for determining whether an injury resulted from a trial and making sure informed consent was properly given. "We don't want a single case of unethical practice", says Y. K. Gupta, a pharmacologist at the All India Institute of Medical Sciences in New Delhi, who is helping to put together the board.
The DCGI has promised to implement most of the panel's suggestions and has presented them to Parliament, which would need to codify the reforms. Already, some changes seem to be occurring; on 24 January, the agency announced that it would approve new clinical trials within six months of their submission. In addition, it clarified that an indemnity insurance requirement -insurance that would have been illegal for the NIH to buy under US law -can instead be purchased by partner institutions within India. Now that the rules are being clarified, Chaudhury hopes that researchers will reconsider their decision to suspend trials.
Yet, until researchers see laws in place, many will remain wary, says Amita Gupta. "I think a lot of groups don't want to deal with the headache. " ■
AN EXAMINED LIFE
A nine-month study will collect data at daily and three-month intervals, and allow personalized interventions -such as changes in diet -as the study proceeds.
LIVER, LUNGS, BRAIN & HEART
• 100 proteins to track organ health • Every three months • Blood sample LYMPHATIC SYSTEM health care that is predictive, preventive, personalized and participatory. Medicine today is a string of infrequent interventions prompted mainly by symptoms of illness. Hood argues instead for continuous management of health, making full use of whole-genome sequencing and biomarkers to correct disease before it gains a foothold.
In March, Hood will embark on the first big test of his ideas: a nine-month pilot study, dubbed the Hundred Person Wellness Project, in which 100 healthy individuals will be intensively monitored (see ' An examined life'), offered regular feedback and counselled on lifestyle changes such as shifts in their dietary or sleep habits. The effects of these behavioural changes on their health will, in turn, be tracked using a battery of diagnostic tests.
The study violates many rules of trial design: it dispenses with blinding and randomization, and will not even have a control group. But Hood is confident in its power to disrupt the conventional practice of medicine. "We hope to develop a whole series of stories about how actionable opportunities have changed the wellness of individuals, or have made them aware of how they can avoid disease, " he says.
If the pilot study works as hoped, it will expand in several phases until it encompasses 100,000 subjects monitored over 25 years. The ISB is paying for the first hundred people through private donations and has budgeted around US$10,000 per person. Hood expects those costs to drop drastically in a larger study, thanks to economies of scale and rapidly evolving diagnostic technologies. But he acknowledges the challenge of securing the hundreds of millions of dollars that a generation-long trial would require. Even in its pilot phase, the project is unusually thorough. The ISB will sequence the whole genome of each participant at the outset. And in later phases, Hood says, the study team will also examine epigenetics: methylation and other modifications to DNA that can reflect environmental exposures. But that is just the tip of the data-collection iceberg.
Participants will be asked to wear digital devices that will continuously record their physical activity, heart rate and sleep patterns; subjects will periodically upload those data to the institute's systems. Every three months, researchers will gather samples of participants' blood, urine, saliva and stool. They will measure five biochemicals in saliva and urine, and sequence the stool samples to track the ecology of major microbial species in the gut. Bloodchemistry screens will extend well beyond the usual tests for cholesterol and glucose to include 20 less-commonly monitored variables, such as C-reactive protein -which signals inflammation at high levels. Hood's teams will also monitor about 100 organ-specific proteins that, he says, are sensitive markers for transitions from health to disease in mouse and cell models.
The point of the study -and of P4 medicine in general -is to detect those transitions and respond to them before symptoms appear. To that end, participants (mostly residents of the Seattle area, invited through social media) will have full access to their personal 'cloud' of data points. Some will have enough scientific training to dive into the literature and interpret their data themselves. But Hood expects most to rely on ISB-provided wellness coaches and their own physicians to interpret the results and recommend medical treatment or changes in diet or behaviour.
"The most amazing thing here is the repeated assessment every three months for some of these markers, " says Graham Colditz, head of the public-health sciences division at Washington University School of Medicine in St Louis, Missouri. Colditz is a former principal investigator of the Nurses' Health Study, which has followed some 120,000 US nurses for 37 years through biennial questionnaires, plus a onetime collection of toenail clippings and two sets of blood samples from a subgroup.
But giving all of the ISB study participants feedback, and pushing them to make changes while the study is under way, risks thwarting the researchers' ability to draw He says that an innovative study of this kind might indeed pick up the earliest hints of disease: "They may not end up proving that all these individuals benefit from the study in one particular way, but they may end up showing that all these individuals benefit from the study in their own individual ways. "
Yet some study participants might have an experience similar to that of Larry Smarr, a computer scientist at the University of California, San Diego, and an early pioneer of the 'quantified self ' movement. For 14 years, he has regularly monitored his biometrics -taking blood, DNA and, most recently, stool samples. He responded to the results by exercising more and radically overhauling his diet. His highly examined life delivered some impressive benefits -he lost 11 kilograms.
But Smarr says that it has also led him to discover alarming spikes in his immune activity, and a strange microbial ecology in his gut. "I had about 10% E. coli; the average healthy person has 0.06%, " he says. Physicians told him he had late-onset Crohn's disease -something that he suspects might have been inflicted by his dietary changes.
Smarr says he would love to participate in the ISB study in the hope of getting his digestive system back on track; Hood says that there are a few spots left and that he is welcome. "I'm 65, so it's questionable whether I'll be around for another 25 years" to see the end of the longterm study, says Smarr. "On the other hand, watching me go bad could be a good thing to have in the database. 
